Pharmacy warning of unsustainable demand for weight loss medication
The NPA, which represents over 6,000 independent community pharmacies, highlighted this concern.
A poll commissioned by the association revealed that 21 per cent of respondents had attempted to access weight loss treatments in the past year, either online or directly from a pharmacy. This figure surged to 35 per cent among 16 to 34-year-olds, contrasting sharply with just seven per cent of those over 55.
There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them.
This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible.
The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services.
NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it.
'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment.
'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.'
Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear.
Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour.
Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS.
Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight.
The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says.
The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed.
They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme.
At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates.
Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice.
'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
22 minutes ago
- New York Times
U.S. Opens Antitrust Investigation Into NewYork-Presbyterian
The Justice Department is investigating whether the renowned NewYork-Presbyterian health system violated antitrust laws through hidden deals with insurance companies that kept hospital prices high, according to a subpoena reviewed by The New York Times. The civil investigation is examining whether NewYork-Presbyterian persuaded insurance companies to agree to conditions that insulated the hospital system from competition — which would enable it to charge more for common procedures with little worry about losing patients. The federal investigation is likely to send a jolt through some of the city's biggest hospitals and the health insurance companies that negotiate with them. The administrative subpoena states that the review seeks to determine if there has been 'potential unlawful agreement between NewYork Presbyterian Health Care System and health insurance companies relating to steering restrictions and contracting conduct.' The investigation is examining a corner of the health industry that has received little attention from antitrust investigators, outside of cases in North Carolina and California in recent years: the negotiations between hospitals and insurers to build a network of providers. NewYork-Presbyterian includes two of the city's most storied medical institutions: Columbia University Medical Center and Weill Cornell Medical Center. The hospitals are affiliated with the medical schools of Columbia and Cornell. The inquiry could lead to more spirited competition among New York City's leading hospital systems, which might translate into lower prices for childbirth, knee replacements, colonoscopies and other common medical care. Want all of The Times? Subscribe.
Yahoo
an hour ago
- Yahoo
UnitedHealth Group (UNH) Responds to the Department of Justice
UnitedHealth Group Incorporated (NYSE:UNH) is one of the top low volatility healthcare stocks to buy now. On July 24, UnitedHealth Group Incorporated (NYSE:UNH) released a statement responding to the Department of Justice after a review of the media reports about investigations into specific aspects of its involvement in the Medicare program. A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated (NYSE:UNH) stated that it has now begun complying with the formal criminal and civil requests from the Department, and has 'full confidence in its practices and is committed to working cooperatively with the Department throughout this process'. It added that UnitedHealth Group Incorporated (NYSE:UNH) has a historical record of 'responsible conduct and effective compliance,' with independent CMS audits showing that its practices are ranked 'among the most accurate in the industry.' Management stated that after a decade-long civil challenge by the Department to aspects of the company's Medicare Advantage business, 'a court-appointed Special Master concluded there was no evidence to support claims of wrongdoing'. UnitedHealth Group Incorporated (NYSE:UNH) has launched its own initiative to provide confidence and transparency to stakeholders, focusing on conducting 'third-party reviews of policies, practices, and associated processes and performance metrics for risk assessment coding, managed care practices, and pharmacy services.' UnitedHealth Group Incorporated (NYSE:UNH) provides healthcare coverage, data consultancy, and software services. It operates through the OptumRx, OptumInsight, OptumHealth, and UnitedHealthCare segments, which have solid operations. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Medscape
an hour ago
- Medscape
Clinical Case: Kidney Cancer Hides in 6-mm Breast Lesion
A 54-year-old woman with a history of renal cell carcinoma (RCC) developed a metastatic lesion in her breast 6 years after radical nephrectomy. The lesion, initially detected via routine imaging, was confirmed as RCC by histopathology and immunohistochemistry. This case report by Aman Saswat Sahoo, a fourth-year Medicine & Surgery undergraduate at the University of Central Lancashire, School of Medicine and Dentistry, Preston, England, and colleagues, highlighted the need for meticulous diagnostic evaluation to distinguish between primary breast carcinoma and metastatic disease, particularly in patients with a history of RCC. The Patient and Her History The patient had a history of RCC that was initially treated with radical nephrectomy and no chemotherapy. She had undergone regular CT imaging since her surgery 3 years ago, and routine CT identified a 4-mm lesion in the lower outer quadrant of the right breast. No other relevant preexisting medical conditions were reported. Her medical, family, travel, allergy, social, and drug histories were unremarkable. Findings and Diagnosis A clinical examination revealed no palpable abnormalities in both breasts. Mammography revealed a 6-mm nodule in the posterolateral region of the right breast, which was absent on a prior mammogram conducted 4 years earlier. Ultrasound imaging confirmed the presence of a solid nodule measuring approximately 5 mm in size. Ultrasound evaluation correlated these findings with a 5-mm benign-appearing nodule. A core biopsy was performed, and histopathologic evaluation showed an inflammatory lesion, characterised by cells with clear cytoplasm and macrophages. Considering the initial diagnosis, immunohistochemical staining provided crucial diagnostic clarity, with positive results for PAX8, CD10, and MNF116 markers, confirming metastatic RCC. Given the patient's history, these findings confirmed the presence of metastatic RCC in the right breast. The patient was informed of the diagnosis of metastatic RCC in the right breast. Further assessment of distant sites and the potential for systemic therapy were discussed at this stage; however, it was later decided that no systemic interventions would be pursued. Although the lesion was considered minor in terms of surgical intervention, its identification is crucial as an indicator of metastatic disease. Wide local excision was performed after tagging the lesion with a radiofrequency identification tag located 3 mm inferior to the original site; no axillary surgery was performed. Postoperative histopathologic evaluation revealed a 5-mm well-circumscribed metastatic RCC. No vascular invasion, ductal carcinoma in situ, or lobular carcinoma in situ was identified. Discussion Although RCC is prominent in its ability to spread haematogenously, metastasis to the breast is extremely uncommon. The route for metastasis usually includes the migration of tumour cells from the kidneys through the inferior vena cava to the right ventricle of the heart. From here on, they enter the pulmonary circulation and eventually reach the breast. Breast metastasis from RCC is exceedingly rare, with fewer than 60 cases documented in the literature. Although the risk for RCC recurrence is highest within the first 2 years following treatment, metastases to uncommon sites, such as the breast, have been reported even a decade after the initial diagnosis and surgical intervention. 'The limited information available in the literature regarding optimal treatment strategies and patient outcomes for RCC metastasis to the breast highlights the need for further studies to better understand this condition,' the authors wrote.
